[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354370-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354370-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","p-glycoprotein-1-as-a-shared-target-for-resensitizing-drug-resistant-tumor-cells-and-preventing-fibronectin-driven-metastasis","P-glycoprotein 1 as a shared target for resensitizing drug-resistant tumor cells and preventing fibronectin-driven metastasis","","Chemoresistance and metastasis often co-occur, yet are rarely addressed through one shared molecular mechanism, limiting durable cancer treatment outcomes. A mechanism-informed strategy identified a non-cytotoxic natural compound with dual activity. Experiments using protein/mRNA and apoptosis assays, phytochemical profiling, and multiple mouse cancer models showed the compound suppresses P-glycoprotein 1 and pericellular fibronectin assembly, restoring drug sensitivity and inhibiting metastasis. Meta-analysis connected co-elevated FN and Pgp1 to poor prognosis and relapse in early-stage patients.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/p-glycoprotein-1-as-a-shared-target-for-resensitizing-drug-resistant-tumor-cells-and-preventing-fibronectin-driven-metastasis/354370/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/p-glycoprotein-1-as-a-shared-target-for-resensitizing-drug-resistant-tumor-cells-and-preventing-fibronectin-driven-metastasis/354370.png","ImageObject",300,407,{"name":42,"@type":43},"4398046744996","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What shared molecular pathway does the study target to address both chemoresistance and metastasis?","Question",{"text":63,"@type":64},"The work focuses on ERK-dependent P-glycoprotein 1 (Pgp1) as a shared upstream regulator, linking chemoresistance and metastatic competence through downstream mechanisms involving pericellular fibronectin assembly.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why is the identified compound described as non-cytotoxic?",{"text":68,"@type":64},"Mulberroside A restores paclitaxel sensitivity without intrinsic cytotoxicity, demonstrating dual anti-cancer effects while avoiding direct cytotoxic killing in the described experiments.",{"name":70,"@type":61,"acceptedAnswer":71},"How was clinical relevance supported beyond animal models?",{"text":72,"@type":64},"Clinical relevance was investigated using meta-analysis of associated gene signatures, linking co-elevated FN and Pgp1 expression with poor prognosis and relapse in early-stage cancer patients.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354370,1790457011,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":11,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":133,"file_id":134,"file_url":135,"file_type":136,"file_size":137,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":117,"language":138,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":139,"faqs":140,"seo_title":141,"seo_description":12,"update_tm":142,"read_time":104,"preview_page_count":33,"preview_urls":143},4398046744996,"Theranostics 2026, Vol. 16, Issue 13 7288  \nIvyspring  \nInternational Publisher  \nTheranostics  \n2026; 16(13): 7288-7307. doi: 10.7150/thno.131375  \nResearch Paper  \nP-glycoprotein 1 as a shared target for resensitizing drug-resistant tumor cells and preventing fibronectindriven metastasis  \nLi-Tzu Huang1, Li-Hsin Cheng1, Chin-Ho Kuo2􀀍, Chin-Yun Cheng3, Shane-Rong Sheu3, Cheng-Han Yang1, Pei-Chu Shih4, Yi-Syuan Li1, Lin Tseng1, Wei-Ting Hsueh5, Lyh-Jyh Hao6,7, Hung-Chi Cheng1,4􀀍  \n1. The Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, 1 University Road, Tainan 70101, Taiwan.  \n2. Division of Hematology-Oncology, Department of Internal Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi 600, Taiwan.  \n3. The Institute of Biotechnology Research Center, Far East University, Tainan 74448, Taiwan.  \n4. Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, 1 University Road, Tainan 70101, Taiwan.  \n5. Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 70456, Taiwan.  \n6. Department of Endocrinology and Metabolism, Kaohsiung Veteran General Hospital, Tainan Branch, Tainan 71051, Taiwan.  \n7. Department of Optometry, Chung Hwa University of Medical Technology, Tainan 71703, Taiwan.  \n􀀍 Corresponding authors: Hung-Chi Cheng and Chin-Ho Kuo, Email: [hungchi@mail.ncku.edu.tw](hungchi@mail.ncku.edu.tw) (Hung-Chi Cheng); [05741@cych.org.tw](05741@cych.org.tw) (Chin-Ho Kuo) .  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2026.01.13; Accepted: 2026.05.05; Published: 2026.06.04  \nAbstract  \nRationale: The exacerbation of chemoresistance and metastasis by synthetic cytotoxic reagents hinders effective cancer therapy, as these events often coincide and lead to poor clinical outcomes, yet are rarely targeted through a shared molecular mechanism. To address this, we established a mechanism-informed natural compound discovery strategy to identify a non-cytotoxic candidate with dual functionality, namely re-sensitizing drug-resistant tumor cells and preventing metastasis.  \nMethods: Western blot, RT-qPCR, and flow cytometry were used for evaluating protein and mRNA expression, as well as cell apoptosis, while GC/MS and HPLC analyses for identifying active phytochemicals from extracts of traditional Chinese medicines. Therapeutic potential was validated in multiple mouse cancer models, including K-rasLSL-G12D/+; p53fl/fl mice. Clinical relevance was investigated via meta-analysis of associated gene signatures.  \nResults: Mulberroside A (Mul A) from Cortex Mori Radices was identified as an ideal compound that inhibits P-glycoprotein 1 (Pgp1) in adherent tumor cells and pericellular fibronectin (periFN) assembly on suspended tumor cells (STCs), which drive drug resistance and metastasis, respectively. Using a paclitaxel (PTX)-resistant Lewis lung carcinoma cell line, we demonstrated that ERK-dependent Pgp1 functions as a shared upstream regulator of both chemoresistance and metastatic competence. Accordingly, Mul A inhibited Pgp1 mRNA and protein levels in an ERK-dependent manner, thereby differentially restoring PTX sensitivity both in vitro and in vivo, without intrinsic cytotoxicity, and significantly inhibiting lung metastasis by reducing the Pgp1–XIAP–periFN axis in STCs. Oral administration of Mul A achieved these dual anti-cancer effects in both experimental and spontaneous mouse models. Importantly, meta-analysis of clinical datasets further linked co-elevated FN and Pgp1 expression with poor prognosis and relapse in early-stage cancer patients, underscoring the translational relevance o","cbCaioiifGPEOTTJ","https://ap.wps.com/l/cbCaioiifGPEOTTJ","pdf",27796218,"English","# Abstract\n## Rationale\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Background and clinical challenge\n## Limitations of current therapies","[{\"question\":\"What shared molecular pathway does the study target to address both chemoresistance and metastasis?\",\"answer\":\"The work focuses on ERK-dependent P-glycoprotein 1 (Pgp1) as a shared upstream regulator, linking chemoresistance and metastatic competence through downstream mechanisms involving pericellular fibronectin assembly.\"},{\"question\":\"Why is the identified compound described as non-cytotoxic?\",\"answer\":\"Mulberroside A restores paclitaxel sensitivity without intrinsic cytotoxicity, demonstrating dual anti-cancer effects while avoiding direct cytotoxic killing in the described experiments.\"},{\"question\":\"How was clinical relevance supported beyond animal models?\",\"answer\":\"Clinical relevance was investigated using meta-analysis of associated gene signatures, linking co-elevated FN and Pgp1 expression with poor prognosis and relapse in early-stage cancer patients.\"}]","P-glycoprotein 1 as a shared target for resensitizing drug-resistant tumor cells and preventing fibronectin-driven metastasis | PDF",1790110347,[144,148,152,156],{"page_no":22,"url":145,"width":146,"height":147},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c089aa61cc45b7333e46460e91851aa4.webp",983,1272,{"page_no":26,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d66889b28acec60d0b237923ac60dce1.webp",982,1270,{"page_no":30,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b52f599ce69f3217cf48bbd29918838c.webp",981,1269,{"page_no":33,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6d7b178303300fbfd9ff71f5c12ec4f.webp",980,1268]